TB-500 Fragment (17-23) is a research peptide consisting of a short amino acid sequence derived from the actin-binding region of Thymosin Beta-4. It has been shown in preclinical studies to regulate cell migration, angiogenesis, and cytoskeletal organization through modulation of actin polymerization. This fragment is used in experimental research investigating wound repair, tissue remodeling, and peptide-mediated regenerative signaling mechanisms.
For research use only. Not for human consumption.
References:
Goldstein AL et al., Ann NY Acad Sci, 2007 1112:148–154
Huff T et al., J Mol Biol, 2001 312(3):593–606
Malinda KM et al., FASEB J, 1999 13(14):2106–2114
TB-500 Fragment (17-23), also called fequesetide or (17) (LKKTETQ) (23), represents the smallest portion of the thymosin beta-4 molecule that retains the larger protein’s active binding domain. Research indicates that this synthetic derivative of thymosin beta-4 is capable of binding to actin, the molecule inside of cells that is responsible for improved cell structure, movement (a.k.a. migration), and replication. By altering the function of actin in cells, TB-500 Fragment (17-23) has been shown to modulate the immune response and alter cell migration patterns. This can lead to large-scale changes in tissue/organ structure and function. In animal models, these changes have been shown to accelerate wound healing, decrease inflammation, promote blood vessel growth, reduce scar formation, improve musculoskeletal function, and help to slow or reverse the course of certain disease conditions.
Reviews
There are no reviews yet.